Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07569198Phase 2Not Yet Recruiting

Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)

Role: lead

NCT05339074Phase 2Completed

Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression

Role: lead

NCT05004896Phase 2Completed

Ketamine for Treatment-Resistant Bipolar Disorder

Role: lead

All 3 trials loaded